Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
Business Wire•13/11/2026•07:00 ET
0
Key Highlights
- ➤ZL-1503 achieved at least 90% pSTAT6 inhibition through Week 12 at 200–1,000 mg
- ➤ZL-1503 showed approximately 40–50-day serum half-life, supporting potential 12-week dosing
- ➤ZL-1503 was well tolerated without serious adverse events or detectable anti-drug antibodies
- ➤Part B multiple-ascending-dose data in moderate-to-severe atopic dermatitis expected in first half of 2027
Expert Statements
Rafael G. Amado, M.D., President and Head of Global Research and Development at Zai Lab
“These first-in-human findings reinforce the potential of ZL-1503 as a differentiated, first-in-class treatment option for patients with atopic dermatitis”
Rafael G. Amado, M.D., President and Head of Global Research and Development at Zai Lab
“By combining two clinically validated mechanisms in a single, half-life-extended bispecific, ZL-1503 has the potential to control inflammation, deliver rapid and durable itch relief, and enable less frequent dosing.”
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
* A single dose of ZL-1503, across dose levels from 200 to 1,000 mg, produced near-complete (≥90%) inhibition of IL-13-stimulated pSTAT6 in healthy volunteers for at least 3 months
Get started
Create a free account to read the full story.